Alendronate improves QOL of postmenopausal women with osteoporosis.

Hisaya Kawate, Ohnaka Keizo, Masahiro Adachi, Suminori Kono, Hideyuki Ikematsu, Hisashi Matsuo, Kazumi Higuchi, Takehiko Takayama, Ryoichi Takayanagi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

PURPOSE: Postmenopausal osteoporosis causes bone fracture as well as pain, physical, psychological and socially adverse effects, which affects a patient's quality of life (QOL). The effect of alendronate on QOL was investigated compared with that of alfacalcidol in post-menopausal osteoporotic women. PATIENTS AND METHODS: A total of 44 postmenopausal osteoporotic women (mean age 69.8 years) with back or joint pain, although capable of walking, were randomly assigned to two groups; group A (n=25) received 5 mg/day of alendronate, and group B (n=19) received 0.5 microg/day of alfacalcidol, for the first 4 months. For the following 2 months, the group A received 0.5 microg/day of alfacalcidol and the group B received 5 mg/day of alendronate in a crossover design. The patient's QOL was evaluated by score of Japanese Osteoporosis Quality of Life Questionnaire (JOQOL), and pain intensity using a visual analog scale (VAS). Bone metabolism was measured by bone mineral density (BMD) and a biomarker for bone resorption, urinary crosslinked N-terminal telopeptide of type I collagen (NTX). RESULTS: With 4-month treatment, alendronate, but not alfacalcidol, improved pain-related QOL, reduced joint pain by VAS, and increased bone mineral density. Both treatments significantly reduced bone resorption, the inhibition was significantly higher with alendronate (-56.5%) compared with alfacalcidol (-18.1%). After crossover, the patients in group A received alfacalcidol and had a reduced total and daily living activity-related QOL scores, and increased upper back pain by VAS. The group B received alendronate had significantly reduced bone resorption after the 2 months. CONCLUSION: Alendronate improves the QOL of Japanese postmenopausal women with osteoporosis by reducing pain intensity as well as increasing bone mineral density.

Original languageEnglish
Pages (from-to)123-131
Number of pages9
JournalClinical interventions in aging
Volume5
Publication statusPublished - Jan 1 2010

Fingerprint

Alendronate
Osteoporosis
Quality of Life
Bone Resorption
Visual Analog Scale
Bone Density
Pain
Arthralgia
Back Pain
Postmenopausal Osteoporosis
Bone Fractures
Activities of Daily Living
Cross-Over Studies
Walking
alfacalcidol
Biomarkers
Psychology
Bone and Bones
Therapeutics

All Science Journal Classification (ASJC) codes

  • Geriatrics and Gerontology

Cite this

Kawate, H., Keizo, O., Adachi, M., Kono, S., Ikematsu, H., Matsuo, H., ... Takayanagi, R. (2010). Alendronate improves QOL of postmenopausal women with osteoporosis. Clinical interventions in aging, 5, 123-131.

Alendronate improves QOL of postmenopausal women with osteoporosis. / Kawate, Hisaya; Keizo, Ohnaka; Adachi, Masahiro; Kono, Suminori; Ikematsu, Hideyuki; Matsuo, Hisashi; Higuchi, Kazumi; Takayama, Takehiko; Takayanagi, Ryoichi.

In: Clinical interventions in aging, Vol. 5, 01.01.2010, p. 123-131.

Research output: Contribution to journalArticle

Kawate, H, Keizo, O, Adachi, M, Kono, S, Ikematsu, H, Matsuo, H, Higuchi, K, Takayama, T & Takayanagi, R 2010, 'Alendronate improves QOL of postmenopausal women with osteoporosis.', Clinical interventions in aging, vol. 5, pp. 123-131.
Kawate H, Keizo O, Adachi M, Kono S, Ikematsu H, Matsuo H et al. Alendronate improves QOL of postmenopausal women with osteoporosis. Clinical interventions in aging. 2010 Jan 1;5:123-131.
Kawate, Hisaya ; Keizo, Ohnaka ; Adachi, Masahiro ; Kono, Suminori ; Ikematsu, Hideyuki ; Matsuo, Hisashi ; Higuchi, Kazumi ; Takayama, Takehiko ; Takayanagi, Ryoichi. / Alendronate improves QOL of postmenopausal women with osteoporosis. In: Clinical interventions in aging. 2010 ; Vol. 5. pp. 123-131.
@article{d6448eefbdf64732ae92c75d6b03b030,
title = "Alendronate improves QOL of postmenopausal women with osteoporosis.",
abstract = "PURPOSE: Postmenopausal osteoporosis causes bone fracture as well as pain, physical, psychological and socially adverse effects, which affects a patient's quality of life (QOL). The effect of alendronate on QOL was investigated compared with that of alfacalcidol in post-menopausal osteoporotic women. PATIENTS AND METHODS: A total of 44 postmenopausal osteoporotic women (mean age 69.8 years) with back or joint pain, although capable of walking, were randomly assigned to two groups; group A (n=25) received 5 mg/day of alendronate, and group B (n=19) received 0.5 microg/day of alfacalcidol, for the first 4 months. For the following 2 months, the group A received 0.5 microg/day of alfacalcidol and the group B received 5 mg/day of alendronate in a crossover design. The patient's QOL was evaluated by score of Japanese Osteoporosis Quality of Life Questionnaire (JOQOL), and pain intensity using a visual analog scale (VAS). Bone metabolism was measured by bone mineral density (BMD) and a biomarker for bone resorption, urinary crosslinked N-terminal telopeptide of type I collagen (NTX). RESULTS: With 4-month treatment, alendronate, but not alfacalcidol, improved pain-related QOL, reduced joint pain by VAS, and increased bone mineral density. Both treatments significantly reduced bone resorption, the inhibition was significantly higher with alendronate (-56.5{\%}) compared with alfacalcidol (-18.1{\%}). After crossover, the patients in group A received alfacalcidol and had a reduced total and daily living activity-related QOL scores, and increased upper back pain by VAS. The group B received alendronate had significantly reduced bone resorption after the 2 months. CONCLUSION: Alendronate improves the QOL of Japanese postmenopausal women with osteoporosis by reducing pain intensity as well as increasing bone mineral density.",
author = "Hisaya Kawate and Ohnaka Keizo and Masahiro Adachi and Suminori Kono and Hideyuki Ikematsu and Hisashi Matsuo and Kazumi Higuchi and Takehiko Takayama and Ryoichi Takayanagi",
year = "2010",
month = "1",
day = "1",
language = "English",
volume = "5",
pages = "123--131",
journal = "Clinical Interventions in Aging",
issn = "1176-9092",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Alendronate improves QOL of postmenopausal women with osteoporosis.

AU - Kawate, Hisaya

AU - Keizo, Ohnaka

AU - Adachi, Masahiro

AU - Kono, Suminori

AU - Ikematsu, Hideyuki

AU - Matsuo, Hisashi

AU - Higuchi, Kazumi

AU - Takayama, Takehiko

AU - Takayanagi, Ryoichi

PY - 2010/1/1

Y1 - 2010/1/1

N2 - PURPOSE: Postmenopausal osteoporosis causes bone fracture as well as pain, physical, psychological and socially adverse effects, which affects a patient's quality of life (QOL). The effect of alendronate on QOL was investigated compared with that of alfacalcidol in post-menopausal osteoporotic women. PATIENTS AND METHODS: A total of 44 postmenopausal osteoporotic women (mean age 69.8 years) with back or joint pain, although capable of walking, were randomly assigned to two groups; group A (n=25) received 5 mg/day of alendronate, and group B (n=19) received 0.5 microg/day of alfacalcidol, for the first 4 months. For the following 2 months, the group A received 0.5 microg/day of alfacalcidol and the group B received 5 mg/day of alendronate in a crossover design. The patient's QOL was evaluated by score of Japanese Osteoporosis Quality of Life Questionnaire (JOQOL), and pain intensity using a visual analog scale (VAS). Bone metabolism was measured by bone mineral density (BMD) and a biomarker for bone resorption, urinary crosslinked N-terminal telopeptide of type I collagen (NTX). RESULTS: With 4-month treatment, alendronate, but not alfacalcidol, improved pain-related QOL, reduced joint pain by VAS, and increased bone mineral density. Both treatments significantly reduced bone resorption, the inhibition was significantly higher with alendronate (-56.5%) compared with alfacalcidol (-18.1%). After crossover, the patients in group A received alfacalcidol and had a reduced total and daily living activity-related QOL scores, and increased upper back pain by VAS. The group B received alendronate had significantly reduced bone resorption after the 2 months. CONCLUSION: Alendronate improves the QOL of Japanese postmenopausal women with osteoporosis by reducing pain intensity as well as increasing bone mineral density.

AB - PURPOSE: Postmenopausal osteoporosis causes bone fracture as well as pain, physical, psychological and socially adverse effects, which affects a patient's quality of life (QOL). The effect of alendronate on QOL was investigated compared with that of alfacalcidol in post-menopausal osteoporotic women. PATIENTS AND METHODS: A total of 44 postmenopausal osteoporotic women (mean age 69.8 years) with back or joint pain, although capable of walking, were randomly assigned to two groups; group A (n=25) received 5 mg/day of alendronate, and group B (n=19) received 0.5 microg/day of alfacalcidol, for the first 4 months. For the following 2 months, the group A received 0.5 microg/day of alfacalcidol and the group B received 5 mg/day of alendronate in a crossover design. The patient's QOL was evaluated by score of Japanese Osteoporosis Quality of Life Questionnaire (JOQOL), and pain intensity using a visual analog scale (VAS). Bone metabolism was measured by bone mineral density (BMD) and a biomarker for bone resorption, urinary crosslinked N-terminal telopeptide of type I collagen (NTX). RESULTS: With 4-month treatment, alendronate, but not alfacalcidol, improved pain-related QOL, reduced joint pain by VAS, and increased bone mineral density. Both treatments significantly reduced bone resorption, the inhibition was significantly higher with alendronate (-56.5%) compared with alfacalcidol (-18.1%). After crossover, the patients in group A received alfacalcidol and had a reduced total and daily living activity-related QOL scores, and increased upper back pain by VAS. The group B received alendronate had significantly reduced bone resorption after the 2 months. CONCLUSION: Alendronate improves the QOL of Japanese postmenopausal women with osteoporosis by reducing pain intensity as well as increasing bone mineral density.

UR - http://www.scopus.com/inward/record.url?scp=77955297766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955297766&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 123

EP - 131

JO - Clinical Interventions in Aging

JF - Clinical Interventions in Aging

SN - 1176-9092

ER -